AI tool aims to revolutionize lung cancer screening

NCT ID NCT07408531

Recruiting now Diagnosis Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study is testing whether an artificial intelligence tool called Sybil can improve lung cancer screening by better predicting who is at risk. Researchers will analyze low-dose CT scans from 2,500 people aged 50-80 and compare AI results with current screening guidelines. The goal is to see if AI can catch more cancers earlier, especially in people not covered by standard recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sybil Artificial Intelligence (AI) screening tool
What this could lead to: If successful, this could lead to more accurate and inclusive lung cancer screening, catching more cases early in people who currently fall outside standard guidelines.
What could go wrong: This is an early-stage observational study, not a treatment trial. The AI tool may not perform better than current methods, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER SCREENING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER SCREENING

Contacts and locations

Locations

UI Health
RECRUITING

Chicago, Illinois, 60612, United States
UI Health 55th and Pulaski Health Collaborative
RECRUITING

Chicago, Illinois, 60629, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.